A detailed history of Graham Capital Management, L.P. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 16,873 shares of APLS stock, worth $562,208. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,873
Previous 5,237 222.19%
Holding current value
$562,208
Previous $200,000 143.0%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $335,582 - $478,821
11,636 Added 222.19%
16,873 $486,000
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $57,295 - $89,863
-1,505 Reduced 22.32%
5,237 $200,000
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $373,439 - $488,592
6,742 New
6,742 $396,000
Q2 2022

Aug 15, 2022

BUY
$35.07 - $59.21 $199,548 - $336,904
5,690 Added 16.24%
40,720 $1.84 Million
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $1.24 Million - $1.9 Million
35,030 New
35,030 $1.78 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.66B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.